GLP-1 receptor agonists were originally developed for type 2 diabetes and obesity, but researchers noticed they also improved liver markers
Figure 3 illustrates the results of semaglutide treatment in obesity and cardiometabolic disease, including its impact on glycemic control, appetite regulation, liver fat, and cardiovascular endpoints
A few more serious side effects, like pancreatitis and thyroid C-cell tumors, did appear in some trials, but more testing is needed
This is why we prioritize delivery methods that bypass the harsh environment of the digestive tract
A moisturizer can be applied before or after to buffer ('sandwich' method)
patients also use it as needed for desire and arousal support